Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

Special Report

NeurologyLive Peer Exchange

Medcast

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Expert Authors

FDA News

Features

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

Articles

Overall, Vidofludimus calcium demonstrated a 20% reduction in confirmed disability worsening events and modest benefits on brain volume change in patients with progressive multiple sclerosis.

Vidofludimus Calcium Demonstrates Therapeutic Potential in Latest Phase 2 CALLIPER Trial Data of Progressive Multiple Sclerosis

Explore the latest advancements in cell and gene therapies for Parkinson disease, featuring cutting-edge treatments and clinical trial updates from top innovators in the field.

The Next Frontier in Parkinson Disease Care: Exploring Gene and Cell Therapies

The REGENERATE-PD trial is a phase 2 study assessing the safety and efficacy of the investigational gene therapy AB-1005 in patients with moderate-stage Parkinson disease.

Investigating Therapeutic Potential of Gene Therapy AB-1005 in Moderate Parkinson Disease: The REGENERATE-PD Trial

Administered intravenously in a single-dose vial, nipocalimab becomes the second FDA-approved therapy for common forms of generalized myasthenia gravis, and the first for younger patients living with the disease.

FDA Approves FcRn Blocker Nipocalimab for Broad Forms of Generalized Myasthenia Gravis

Move fast—April 30, 2025, is the final day to take advantage of early bird savings!

Register Today for the 2025 CMSC Annual Meeting in Phoenix!

Videos

The chief scientific officer of the Parkinson’s Foundation talked about how broad genetic testing through PD GENEration is uncovering valuable prognostic and diagnostic insights in Parkinson disease. [WATCH TIME: 4 minutes]

Illuminating Genetic Insights in Parkinson Disease Through PD GENEration: James Beck, PhD

, has been with the team since September 2022. Follow her on Twitter 

Bruce Bebo, PhD, and Amit Bar-Or, MD, FRCPC, FAAN, FANA, discussed the impact of the John Dystel Prize on multiple sclerosis research and its role in shaping future clinical advancements. 

Advancing MS Research Through Recognition and Innovation: The John Dystel Prize

Founder and Executive Director, Sumaira Foundation

The founder and executive director of the Sumaira Foundation emphasized the critical role of lifestyle factors such as sleep, exercise, and nutrition for maintaining brain health in patients with NMOSD. [WATCH TIME: 3 minutes]

Prioritizing Brain Health in NMOSD Beyond Disease-Modifying Therapies: Sumaira Ahmed

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

LinkedIN

YouTube

Spotlight

AAN 2025

AD/PD 2025

MDA 2025

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

News Network

1rem

View

Cure SMA

SAP Partners

Episode 1: Overview of Telehealth in Clinical Practice and Patient Options

Episode 2: How Telehealth Can Improve Care for Patients With SMA

Episode 3: Utilizing Telehealth to Conduct Multidisciplinary Visits in SMA Care

Episode 4: The Limitations of Telehealth for Treating SMA

Episode 5: The COVID-19 Pandemic's Effect on Telehealth Use for SMA

Episode 6: Easing the Process of Learning to Use, Incorporate Telehealth in Practice

Episode 7: Prepping Patients With SMA and Their Families Prior to Telehealth Visits

Episode 8: Proposed Solutions to the Limitations of Telehealth

Episode 9: Maximizing Patient Engagement During Telehealth Visits

Episode 10: How Telehealth Provides Insight, Perspective on At-Home Challenges

Episode 11: Resources Available for Patients With SMA 

Cure SMA is dedicated to the treatment and care of spinal muscular atrophy (SMA). Since 1984, Cure SMA has grown to be the largest network of individuals, families, clinicians, and research scientists working together to advance SMA research, support the full SMA community, and educate the public and professional communities about SMA. The organization has directed and invested in comprehensive research that has shaped the scientific community's understanding of SMA, led to breakthroughs in treatment and care, and provides individuals and families the support they need today. For more information, visit 

SAP Partner

Clinical

Lessons Learned in Telehealth When Implementing Multidisciplinary Care for Patients Affected by SMA